Accounts in Drug Discovery: Case Studies in Medicinal Chemistry
Accounts in Drug Discovery describes recent case studies in medicinal chemistry with a particular emphasis on how the inevitable problems that arise during any project can be surmounted or overcome. The Editors cover a wide range of therapeutic areas and medicinal chemistry strategies, including lead optimization starting from high-throughput screening "hits" as well as rational, structure-based design. The chapters include "follow-ons" and "next generation" compounds that aim to improve upon first-generation agents. This volume surveys the range of challenges commonly faced by medicinal chemistry researchers, including the optimization of metabolism and pharmacokinetics, toxicology, pharmaceutics and pharmacology, including proof-of-concept in the clinic for novel biological targets. The case studies include medicinal chemistry stories on recently approved and marketed drugs, but also chronicle "near-misses," i.e. exemplary compounds that may have proceeded well into the clinic but for various reasons did not result in a successful registration. As the vast majority of projects fail prior to registration, much can be learned from such narratives. By sharing a wide range of drug discovery experiences and information across the community of medicinal chemists in both industry and academia, the Editors believe that these accounts will provide insights into the art of medicinal chemistry as it is currently practiced and will help to serve the needs of active medicinal chemists.
What people are saying - Write a review
We haven't found any reviews in the usual places.
The Discovery of the Dipeptidyl Peptidase4 DPP4
RSC Drug Discovery Series No 4
The Discovery of OSI906 a Smallmolecule Inhibitor of
The Genesis of the Antibody Conjugate Gemtuzumab
Novel Androgen Receptor Antagonists for the Treatment
the Challenge of Targeting
The Discovery of the Longacting PDE5 Inhibitor PF489791
the Discovery and Development
The Discovery of GS9131 an Amidate Prodrug of
20F20CMethyl Nucleosides and Nucleotides for
Other editions - View all
a7 nAChR acid aﬃnity aﬀorded agents amide amine analogs antibody antiviral activity assay bicalutamide binding bioavailability Bioorg calicheamicin capsaicin CCR5 cells Chem Cl Cl clearance Clin clinical Cmax compound conjugate demonstrated derivatives diabetes diﬀerent DPP4 Drug Discovery duloxetine eﬀects eﬃcacy eﬀorts enzyme evaluated exposure Figure ﬁndings ﬁrst gemtuzumab ozogamicin glucose H H H half-life hERG hyperthermia identiﬁed improved increase inhibition inhibitors interactions kinase lead Lett levels ligand lipophilic maraviroc Medicinal Chemistry metabolism metabolite moiety molecule monkey mutation N(t)RTIs nucleoside observed oral bioavailability patients PDE5 pharmacokinetic Pharmacol phenyl plasma concentration platelet potency preclinical prodrug proﬁle protein quinuclidine rapamycin result ring safety saxagliptin screening selectivity showed signiﬁcant signiﬁcantly Society of Chemistry speciﬁc SSRIs stability strategy structure studies substitution Table target therapy thrombin receptor toxicity treatment TRPV1 tumor viral vitro vivo Wang